Poor
Not Aligned
Patient Risk:
Medium
Summary
The response makes many specific mechanistic, quantitative, and clinical-detail claims that are not supported by the provided FDA label excerpts. Some general statements about grapefruit juice increasing atorvastatin plasma concentrations via CYP3A4 inhibition and increasing myopathy risk with larger grapefruit juice quantities (>1 liter) are supported, but most additional claims (e.g., exact thresholds >1.2 L/day, duration up to 3 days, 'only' CYP3A4-broken-down drugs, statements about specific alternate statins not using CYP3A4, symptom frequency, and claims about liver enzyme changes tied to grapefruit) are not substantiated by the supplied text.
Category Scores
Accurate Statements
Grapefruit juice can increase plasma concentrations of atorvastatin (Lipitor).
7.2 Grapefruit Juice: '...can increase plasma concentrations of atorvastatin...'
Grapefruit juice contains components that inhibit CYP 3A4.
7.2 Grapefruit Juice: 'Contains one or more components that inhibit CYP 3A4...'
The risk of myopathy increases with consuming larger quantities (>1 liter) of grapefruit juice.
17.1 Muscle Pain: '...increased when taking certain types of medication or consuming larger quantities (>1 liter) of grapefruit juice.'
Unsupported Statements
Grapefruit juice raises Lipitor levels by temporarily blocking the CYP3A4 enzyme.
Label excerpt states grapefruit juice components 'inhibit CYP 3A4' but does not state 'temporarily blocking' or describe kinetics.
CYP3A4 normally helps break down atorvastatin (Lipitor).
The provided label excerpt does not explicitly state CYP3A4's normal role in atorvastatin breakdown.
Higher atorvastatin levels in the body can increase the chance of side effects such as muscle pain and muscle weakness.
The label excerpt ties grapefruit consumption to increased myopathy risk, but does not attribute side effects to 'higher atorvastatin levels' specifically.
Grapefruit juice with Lipitor can increase the chance of liver enzyme changes.
The provided grapefruit juice and muscle pain excerpts do not mention liver enzyme changes due to grapefruit juice; liver section discusses statins broadly.
Grapefruit juice only interferes with medications that are broken down by CYP3A4.
No such limitation is stated in the provided label excerpt.
Lipitor (atorvastatin) is broken down by CYP3A4.
Not stated in the provided label excerpt; it only states grapefruit inhibits CYP3A4 and increases atorvastatin concentrations.
The effect of grapefruit juice on atorvastatin levels can start after one glass of juice.
No time-to-onset or 'one glass' detail is provided.
The effect of grapefruit juice on atorvastatin can last up to three days after the last glass.
No duration information is provided.
The impact of grapefruit juice increases with larger amounts or daily consumption.
Label excerpt supports increased risk with larger quantities (>1 liter) but does not explicitly support 'increases with larger amounts or daily consumption' as a general proportional rule, nor does it quantify beyond the provided threshold.
The interaction between grapefruit juice and Lipitor is rated major by many drug databases.
Not present in the provided label excerpts.
In some cases, the grapefruit juice–Lipitor interaction can lead to rhabdomyolysis.
Label excerpt mentions rare rhabdomyolysis with drugs in this class, but does not specifically connect grapefruit juice to rhabdomyolysis.
Rhabdomyolysis is a serious breakdown of muscle tissue that can send muscle proteins into the kidneys.
Definition/pathophysiology statement is not provided in the supplied excerpts.
Patients who drink grapefruit juice regularly are often advised to avoid it completely while taking Lipitor.
The provided label excerpt does not state 'avoid completely' or characterize advice as 'often'.
Doctors usually recommend switching to an alternative fruit juice or limiting grapefruit consumption to very occasional small amounts while taking Lipitor.
No such practice guidance is provided in the excerpts.
Patients commonly report muscle soreness, cramps, and fatigue when grapefruit juice is combined with Lipitor.
No incidence or frequency (e.g., 'commonly') and no specific symptom list tied to grapefruit interaction is provided.
Some patients also mention digestive upset when grapefruit juice is combined with Lipitor.
No digestive upset tied to grapefruit interaction is provided.
Liver function tests may show temporary rises in enzymes without symptoms in this situation.
While liver enzyme changes are discussed for statins generally, the excerpt does not link these changes 'in this situation' (grapefruit juice interaction).
Rhabdomyolysis remains rare but is reported in cases where patients continue drinking large amounts of grapefruit juice while on Lipitor.
The excerpts do not provide such a causal scenario or mention grapefruit amounts leading to rhabdomyolysis.
Doctors may prescribe a statin that does not interact with CYP3A4, such as pravastatin or rosuvastatin.
No label excerpt provided supports that pravastatin/rosuvastatin do not interact with CYP3A4.
Pravastatin and rosuvastatin are not broken down by the same CYP3A4 enzyme pathway.
Not supported by the provided excerpts.
Patients can avoid grapefruit products entirely while continuing their current statin to prevent this interaction.
The excerpts support increased exposure/risk with grapefruit consumption, but do not provide an instruction that 'avoid grapefruit products entirely' prevents the interaction.
Contradictions
Low
AI Statement
Rhabdomyolysis remains rare but is reported in cases where patients continue drinking large amounts of grapefruit juice while on Lipitor.
Label Reference
5.1 Skeletal Muscle / 7.2 Grapefruit Juice / 17.1 Muscle Pain
Important Omissions
Quantitative grapefruit threshold in the label excerpt is 'especially with excessive grapefruit juice consumption (>1.2 liters per day)' (7.2), which is not consistently and accurately represented across the multi-claim list (e.g., other claims use different thresholds such as '>1 liter' vs '>1.2 liters/day').
Importance:
Moderate
The label excerpt provides liver monitoring recommendations (prior to and at 12 weeks after initiation and after dose increases, then periodically) and guidance on ALT/AST persistence; the response does not align these to any grapefruit-specific claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Some label-supported risk linkage exists (increased myopathy risk with >1 liter grapefruit; increased plasma concentrations), but many additional claims are not supported and could mislead about magnitude, timing, duration, and specific adverse-event expectations (e.g., rhabdomyolysis, digestive upset) without label support.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple mechanistic, quantitative (timing/duration), and clinical outcome/frequency claims are not supported by the provided label excerpts.
Suggested Improvement
Limit statements to what is directly supported by the excerpts: grapefruit juice contains CYP3A4-inhibiting components that increase atorvastatin plasma concentrations, especially with excessive consumption (>1.2 L/day), and the risk of myopathy is increased with larger grapefruit quantities (>1 L). Remove or rewrite unsupported claims about timing (onset/duration), specificity ('only' CYP3A4-pathway drugs), alternate statin lack of CYP3A4 interaction, symptom frequency, digestive upset, and rhabdomyolysis being specifically caused by grapefruit in the provided text.